De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients

Transplant International

Volumn 28, Issue 12, 2015, Pages 1371-1382

  Del Bello, Arnaud ^a,b   Congy Jolivet, Nicolas ^a,b,c   Danjoux, Marie ^d   Muscari, Fabrice ^a,b   Lavayssière, Laurence ^a   Esposito, Laure ^a   Cardeau Desangles, Isabelle ^a   Guitard, Joëlle ^a   Dörr, Gaëlle ^a,b   Milongo, David ^a   Suc, Bertrand ^a,b   Duffas, Jean Pierre ^a   Alric, Laurent ^b,d   Bureau, Christophe ^b,d   Guilbeau Frugier, Céline ^b,d   Rostaing, Lionel ^a,b,d   Kamar, Nassim ^a,b,d  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSERM   (France)

^d CHU PURPAN   (France)

Author keywords

antibody mediated rejection; donor specific antibodies; incidence; liver transplantation; risk factors; treatment

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; IMMUNOGLOBULIN; LIVER ENZYME; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGE; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CHOLESTASIS; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEPATORENAL SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INCIDENCE; LIVER BIOPSY; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; RETRANSPLANTATION; RISK FACTOR; SURVIVAL RATE; ADVERSE EFFECTS; ANTIBODY SPECIFICITY; BLOOD; DONOR; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 84960094646     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12654     Document Type: Article

References (33)

1. Demetris AJ, Nakamura K, Yagihashi A, et al,. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671.
2. Demetris AJ, Murase N, Nakamura K, et al,. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51.
3. Nakamura K, Murase N, Becich MJ, et al,. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383.
4. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW,. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
5. Takaya S, Duquesnoy R, Iwaki Y, et al,. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23: 396.
6. Starzl TE, Demetris AJ, Todo S, et al,. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989; 3: 37.
7. Kozlowski T, Rubinas T, Nickeleit V, et al,. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357.
8. Paterno F, Shiller M, Tillery G, et al,. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526.
9. Musat AI, Pigott CM, Ellis TM, et al,. Pretransplant donor-specific anti-hla antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132.
10. Musat AI, Agni RM, Wai PY, et al,. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.
11. Demetris AJ, Markus BH, Burnham J, et al,. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19: 121.
12. Del Bello A, Congy-Jolivet N, Muscari F, et al,. Prevalence, Incidence and risk factors for Donor Specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867.
13. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al,. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333.
14. Iacob S, Cicinnati VR, Dechene A, et al,. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012; 32: 1253.
15. Kaneku H, O'Leary JG, Banuelos N, et al,. De novo donor specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541.
16. Chin C, Chen G, Sequeria F, et al,. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158.
17. Demetris AJ, Batts KP, Dhillon AP, et al,. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
18. Demetris AJ, Adams D, Bellamy C, Blackolmer K, Clouston A, Dhillon AP,. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000; 31: 792.
19. O'Leary JG, Shiller MS, Bellamy C, et al,. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl 2014; 20: 1244.
20. O'Leary JG, Kaneku H, Jennings LW, et al,. Preformed class II donor-specific antibodies are associated with increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973.
21. Ruiz R, Tomiyama K, Goldstein RM, et al,. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455.
22. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, et al., Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504.
23. O'Leary JG, Kaneku H, Demetris AJ, et al,. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218.
24. Castillo-Rama M, Castro MJ, Bernardo I, et al,. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554.
25. Schaub S, Hönger G, Koller MT, Liwski R, Amico P,. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014; 98: 387.
26. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM,. C1q Binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 2015; 99: 1151.
27. Wiebe C, Gibson IW, Blydt-Hansen TD, et al,. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplantation. Am J Transplant 2012; 12: 1157.
28. Everly MJ, Rebelatto LM, Haisch CE, Ozawa M, ParkerK Briley KP, et al,. Incidence and impact of de novo donor-specific alloantibodies in primary renal allografts. Transplantation 2013; 95: 410.
29. Terasaki PI, Ozawa M,. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
30. Loupy A, Lefaucheur C, Vernerey D, et al,. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215.
31. Fehr T, Gaspert A,. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transplant Int 2012; 25: 623.
32. Kamar N, Lavayssière L, Muscari F, et al,. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426.
33. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki P, Klintmalm GB,. Donor-specific human leucocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984.